R-Pharm Group and PrimeBioMed LLC signed an agreement on joint development of a quantitative immunohistochemical test for the use of drugs blocking PD-1/PD-L1. The immuno-oncological drugs represent a new class of anti-tumor agents that act by stimulating the immune system to destroy tumor cells.
Currently, in the Russian Federation, there are several immune checkpoint inhibitors (anti-CTLA-4, anti-PD1, anti-PDL1), with some of them being already registered, while the others are at the stage of clinical development.
The use of immuno-oncological drugs allows to achieve a long-term response to treatment only in some part of patients with neoplastic diseases. In most cases, the use of immune checkpoint inhibitors should be preceded by testing in order to confirm the existence of a target for the drug.
The goal of the joint project of R-Pharm Group and PrimeBioMed LLC is to develop new reagents that will provide the basis for creating a kit for qualitative and quantitative assessment of the expression of a number of predictive tumor tissue markers by using immunohistochemical method. In addition to the expanded panel of markers, its key difference from commercially available tests will be a system for automatic analysis of results. These components will allow to substantially minimize the assessment bias due to differences in pathologists’ approaches.